Skip to main content

Novaliq Transforms Topical Therapies

Our unique and versatile water-free technology is poised to transform established treatments.

Novaliq is a private pharmaceutical company committed to develop transformational ocular therapies.

We have successfully developed the new drug category of water-free topical eye therapies called EyeSol®. This unique and versatile water-free technology is poised to transform established treatments. EyeSol® products are ocular surface beneficial, micro-dosed and non-preserved.

As a fully integrated, partially virtual biopharmaceutical company we continue to revolutionize ocular treatments to realize the full potential of eye care treatments for the benefit of patients in diseases with high unmet needs.

Transform ocular therapeutics to unfold the full potential of eye care treatments.

  • Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA.

  • The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.

What we do

EyeSol®, Novaliq’s unique and proprietary water-free technology, opens completely new and intriguing opportunities to cure, relief and prevent diseases in various areas of indications for patients.

Our journey started with NovaTears®, the first water-free eye drop based on EyeSol® for the treatment of dry eye. NovaTears® is CE certified since 2013 and successfully commercialized in Europe and in Australia/New Zealand by our partners.

Based on our success in dry eye disease we are now expanding into back of the eye retinal diseases, with an initial focus on revolutionizing the treatment paradigm for diabetic retinopathy.


Set your eyes on us! We are a team of seasoned ophthalmology drug development and market experts exploring the world of water-free therapies to develop transformational ocular therapies. Our vision now is to revolutionize the treatment of diabetic retinopathy drug products developed for topical administration, to preserve eyesight in millions of patients around the globe.

Christian Roesky Ph.D.

Managing Director/Chief Executive Officer

Oliver Schlüter Ph.D.

Managing Director/Chief Financial Officer

Gabriela Burian MD, MPH

Consulting Chief Medical Officer

Dr. Sonja Krösser

VP Medical Science & Regulatory Affairs

Dr. Martin Mauden

Vice President Chemistry, Manufacturing & Control

Dr. Jörg Haißer

Vice President Supply Chain Management & Analytical Development

Karen Pasig

Vice President Finance & Accounting

Supervisory Board

Meet our supervisory board members

Global presence and strategic partnerships

We work with leading academic and industry partners around the globe to bring innovative therapies leveraging our proprietary water-free technology to patients:

Since December 2019, Novaliq has a strategic cooperation with Bausch + Lomb. Bausch has received exclusive rights to develop, manufacture and commercialize NOV03 (perfluorohexyloctane) in USA and Canada.

In May 2023 MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) was approved for the treatment of the signs and symptoms of dry eye disease (DED) in the USA. MIEBO™ is the first and only FDA-approved treatment for DED that directly targets tear evaporation. Please refer to for more information and MIEBO™ prescription information. Approval in Canada is expected in 2024 by Bausch + Lomb.

In 2023 Harrow acquired the U.S. and Canadian commercial rights for VEVYE™ (cyclosporine ophthalmic solution, formerly known as CyclASol®) 0.1%, a patented, non-preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology. VEVYE™ (cyclosporine ophthalmic solution) 0.1% is the first and only cyclosporine ocular therapy to treat both the signs and symptoms of dry eye disease and was approved by FDA in May 2023. Please refer to for more information and VEVYE™ prescription information.

In China, Novaliq has a strategic cooperation with Jiangsu Hengrui Pharmaceuticals since November 2019.

Hengrui has received exclusive rights to develop, manufacture and commercialize NOV03 and CyclASol® for the treatment of dry eye disease in China.

In Japan Novaliq partners with Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), a first-in-class, preservative-free treatment for signs and symptoms of dry eye disease.

In April 2019, Novaliq has founded Betaliq Inc., Tampa, USA in collaboration with BLP Management Group, LLC. Betaliq develops the ophthalmic beta-blocker BTQ 1902 using Novaliq’s proprietary EyeSol® water-free technology. In the US Phase 2 study BTQ-1902 met the study goal of statistical non-inferiority to marketed Timolol 0.5% indicating a strong likelihood of achieving a positive outcome in the final Phase 3 study. BTQ-1902 had an excellent safety profile and was well tolerated. Requirements for NDA filing was confirmed by FDA written correspondence. Betaliq plans to enter Phase 3 with BTQ-1902 (timolol in EyeSol®) soon.

Our journey as a company started by developing a first-in-class, preservative-free topical eye treatment and tear film stabilizer based on perfluorohexyloctane.

These novel water-free products are clinically validated by significant improvement in signs and symptoms in patients with evaporative dry eye disease and Meibomian gland disfunction (MGD) in a number of clinical trials. This new class of water-free products was initially CE certified in 2013 and are successfully commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe by Ursapharm.

Ursapharm is one of the leading EU ophthalmic players.

In October 2015, EvoTears® (perfluorohexyloctane) entered the EU market. EvoTears® has been successfully launched in 17 European countries incl Germany, France, UK, Spain, Italy, Benelux, Poland and Switzerland.

In some countries the product is also known under other brand names: HYLO LIPID™ (France), Hycosan Shield™ (UK).

In January 2020 the novel product EvoTears™ OMEGA with algae derived omega-3 to alleviate irritated eyes and lid margins has been launched in Germany and other countries in Europe.

AFT Pharmaceuticals is a New Zealand-based pharmaceutical company listed in ASX and NZX, and Novaliq’s partner for the commercialization of NovaTears® (perfluorohexyloctane) and NovaTears®+Omega-3 in Australia and New Zealand.

AFT is a leader in the lubricating eyecare category in Australia with sales growth from the NovaTears® family contributing to its growth.

In Australia NovaTears® is PBS listed since September 2018. The PBS Schedule lists all the medicines available to be dispensed to patients at a government-subsidized price.

Academic partners

Novaliq collaborates with leading scientific partners

Prof. Dr. med. Claus Cursiefen in the field of ophthalmic drug delivery for the anterior segment of the eye with special focus on dry eye disease.

Prof. Heping Xu, MD, PhD, in the field of retina diseases.

Dr. Ilva Rupenthal in the field of drug delivery technologies and ocular therapeutics.

Prof. Dr. med. Johannes Wohlrab in the field of penetration and dermatology.

Prof. Dr. Wolfgang Frieß in the field of protein formulation.

Prof. Gordon Tiddy and Dr. Robin Curtis in the field of basic research in formulation sciences.

Novaliq in the U.S.A.